Westminster, CA – December 8, 2021 – BioLargo, Inc.
(OTCQB:BLGO), a developer of sustainable cleantech technologies and
full-service environmental engineering company, has taken the next step to
commercialize the new wastewater treatment technology, called a “minimal liquid
discharge” system, that it designed and manufactured for Garratt-Callahan, a
century-old national water treatment company. In this stage, BioLargo engineers
will process contaminated water with a full-scale prototype of the new
technology to verify its treatment efficacy and durability. Once this stage is
completed successfully, sales can begin to Garratt-Callahan customers.
“We are excited to be working with Garratt-Callahan to
launch this product because of their pedigree of innovation and integrity in
the water industry. Their focus on developing technologies that reduce freshwater
usage aligns with our values of focusing on sustainable solutions above all
else,” said Randall Moore, President of BioLargo Engineering, Science &
Technologies.
Tonya Chandler, BioLargo’s Director of Strategic Marketing
and Business Development, said, “This project highlights our capabilities to
serve customers as an innovator and solutions provider in wastewater treatment.
We helped scale the design of the MLD system, we manufactured it, and now we’re
testing it in our in-house water lab to validate its performance before it
ships to customers.
About BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO) invents, develops, and
commercializes innovative platform technologies to solve challenging
environmental problems like PFAS contamination, advanced water and wastewater
treatment, industrial odor and VOC control, air quality control, and infection
control. With over 13 years of extensive R&D, BioLargo holds a wide array
of issued patents, maintains a robust pipeline of products, and provides
full-service environmental engineering. Our peer-reviewed scientific approach
allows us to invent or acquire novel technologies and develop them to maturity
through our operating subsidiaries. With a keen emphasis on collaborations with
academic, municipal, and commercial organizations and associations, BioLargo
has proven itself with over 80 awarded grants and numerous pilot projects. We
monetize through direct sales, recurring service contracts, licensing
agreements, strategic joint venture formation and/or the sale of the IP. See our
website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include without limitation those about
BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19
pandemic; anticipated revenue; and plans for future operations. These
statements involve risks and uncertainties, and actual results may differ
materially from any future results expressed or implied by the forward-looking
statements. Risks and uncertainties include without limitation: the effect of
the COVID-19 pandemic on the Company’s business, results of operations,
financial condition, and stock price; the effect of regional economic
conditions on the Company’s business, including effects on purchasing decisions
by consumers and businesses; the ability of the Company to compete in markets
that are highly competitive and subject to rapid technological change; the
ability of the Company to manage frequent introductions and transitions of
products and services, including delivering to the marketplace, and stimulating
customer demand for, new products, services, and technological innovations on a
timely basis; the dependency of the Company on the performance of distributors
of the Company’s products. More information on these risks and other potential
factors that could affect the Company’s business and financial results is
included in the Company’s filings with the SEC, including in the “Risk Factors”
and “Management’s Discussion and Analysis of Financial Condition and Results of
Operations” sections of the Company’s most recently filed periodic reports on
Form 10-K and Form 10-Q and subsequent filings. The Company assumes no
obligation to update any forward-looking statements or information, which speak
as of their respective dates.
No comments:
Post a Comment